After US, Germany bans Ranbaxy antibiotic from Dewas plant
04 Dec 2014
In yet another blow to Indian generic drug maker Ranbaxy Laboratories, Germany has barred it from exporting antibiotic cephalosporin from its plant at Dewas in Madhya Pradesh for not complying with standard manufacturing practices.
Germany's regulator issued a 'non-compliance' report for the plant where Ranbaxy made the antibiotic after an inspection in June, the European Medicines Agency said on its website in a notice dated 26 November.
During the inspection, the German regulator found deficiencies related to operation of drug manufacturing rooms and procedures related to sterilisation of equipment at the Dewas site, the notice said.
The Dewas factory and all of Ranbaxy's other India-based plants are also barred from exporting to the United States after US Food and Drug Administration (FDA) inspections found those plants violated its standard manufacturing practices.
Ranbaxy, which has said it is working on resolving problems at its plants to have the regulatory bans lifted, did not respond to a request seeking comment on the observations made by the German regulator.
Ranbaxy gets more than half of its revenue from the United States. Germany accounted for 2 per cent of global sales in the 15-month period ended March, 2014, as per company filings.
(Also see:Ranbaxy hit afresh by FDA; all its India-made products banned)
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
